Stockwinners Market Radar for April 15, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:34 EDT Gold Resource reports Q1 gold sales 3,557 oz. vs. 6,508 oz. last year - Reports Q1 silver sales 216.5K oz vs. 294.8K oz last year. "During the first quarter we continued our process to identify and implement opportunities for cost reductions and operational efficiencies in order to improve profitability. We are also moving forward with our 2024 drill program with the purpose of increasing our resources and reserves that could lead to future production improvements." stated Allen Palmiere, President and CEO. "The Mexican peso has continued to remain strong against the US dollar, but we have seen substantial increases in the metals prices that are more than offsetting the impact of the exchange rate. With the enhancements we are making with our operations and the improvements we are seeing in the metal prices, we are moving in the right direction."

19:50 EDT NuCana PLC (ADR) trading halted, news pending

18:36 EDT Apple COO sells $10.19M in common stock - In a regulatory filing, Apple disclosed that its COO Jeffrey Williams sold 59.2K shares of common stock on April 11th in a total transaction size of $10.19M.

18:34 EDT Exxon Mobil applies to cease being a reporting issuer in Canada - Exxon Mobil has applied to the Alberta Securities Commission - ASC -, as principal regulator, and the Ontario Securities Commission - OSC - for a joint order to cease to be a reporting issuer in each of the provinces of Canada. ExxonMobil is not a reporting issuer in any other Canadian jurisdiction. If the order sought is granted by the ASC and the OSC, ExxonMobil will cease to be a reporting issuer in any jurisdiction in Canada. ExxonMobil will continue to file all financial statements and other continuous disclosure materials required to be filed by it in accordance with the applicable securities laws of the U.S. and the rules of the NYSE. ExxonMobil's security holders resident in Canada will continue to receive copies of the continuous disclosure documents required to be delivered to security holders in the U.S.

17:55 EDT Roth CH Acquisition Co trading halted, news pending

17:45 EDT Live Nation falls 5% to $95 after WSJ report of possible DOJ suit next month

17:13 EDT General Dynamics awarded $296.86M Army contract - General Dynamics was awarded a $296.86M cost-plus-fixed-fee contract for M10 Booker system technical support. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of April 14, 2029. Army Contracting Command is the contracting activity.

17:02 EDT Zevra Therapeutics presents new data from arimoclomoal EAP - Zevra Therapeutics announced that new long-term real-world data from the arimoclomol expanded access program for the treatment of Niemann-Pick disease type C was featured in an oral presentation during the Society for Inherited Metabolic Disorders 45th Annual Meeting taking place at the Sheraton/Le Meridien Charlotte Hotel Complex in Charlotte, NC, from April 14-17, 2024. "These real-world data collected in the arimoclomol US EAP represent the first evidence to support the use of arimoclomol in adults with NPC, demonstrating a clinically meaningful slowing of disease progression," noted Kristina Julich, M.D., Assistant Professor, Department of Neurology, at The University of Texas at Austin, Dell Medical School. "NPC presents a therapeutic challenge, lacking approved treatment options in the U.S. and invariably leading to progressive loss of independence due to physical and cognitive impairments. We are very pleased with the positive new data that brings hope for a community with a high unmet medical need." "These observed long-term clinical benefits add to the body of evidence for arimoclomol that supports its tolerability and effectiveness in the treatment of NPC, bringing us one step closer to helping patients suffering from this relentless and fatal disease," remarked Neil F. McFarlane, President and Chief Executive Officer of Zevra. "We remain committed to continue collaborating closely with the FDA as it reviews arimoclomol's NDA ahead of our PDUFA date on September 21, 2024."

16:54 EDT NuStar Energy declares conditional special distribution of 21.2c per unit - NuStar Energy (NS) announced that the board of directors of NuStar GP, the general partner of its general partner, has declared a special distribution of 21.2c per NuStar Energy common unit, to be paid on May 2 to holders of record of NuStar Energy common units as of April 26. Payment of the special distribution is subject to and conditioned upon holders of NuStar Energy's common units approving its acquisition by Sunoco (SUN) at NuStar Energy's special meeting on May 1, and the merger agreement with respect to the acquisition not having been terminated. If approval of the pending acquisition is not obtained at the special meeting or the merger agreement with respect to the acquisition is terminated, the special distribution will not be paid until a date, and to holders of record, later determined by the board of directors of NuStar GP, or it may not be paid at all.

16:36 EDT First Watch Restaurant completes acquisition of franchise-owned sites for $75M - First Watch Restaurant Group announced the completion of its previously-announced acquisition of 21 of its franchise-owned restaurants and corresponding development rights in North Carolina for an aggregate purchase price of $75 M on a cash-free, debt-free basis. "This acquisition, which represents our largest First Watch franchise acquisition to date, is an important part of our long-term growth and value creation strategy," said Chris Tomasso, First Watch CEO & President. "These 21 restaurants are expected to generate average unit volumes and restaurant level operating profit margins in line with our Company-owned restaurants, and the associated development rights represent white space in this key market area for us to grow organically for years to come. Further, this acquisition fortifies our organization and strengthens our ranks as we welcome more than 600 new employees into our corporate-owned system and You First culture-a responsibility that's very important to us...First Watch has acquired 44 total franchised restaurants in 17 DMAs across six acquisitions since May 2023.

16:33 EDT SHF Holdings board appoints CEO Sundie Seefried, as Board member - SHF Holdings, Inc., d/b/a/ Safe Harbor Financial announced that its Board of Directors has appointed its Chief Executive Officer, Sundie Seefried, as a member of the Board. Seefried was appointed in order to fill the vacancy created by John Darwin's resignation as a member of the Board. Mr. Darwin's resignation was not in connection with any known disagreement with the Company on any matter relating to the Company's operations, policies, or practices.Fred Niehaus, Chairman of the Board, stated, "It was a natural fit for Sundie to be appointed to fill a vacancy on the Board, given her extensive expertise of cannabis finance and ongoing success in creating a pathway for compliant banking and financial services for cannabis-related businesses. As a 39-year financial industry veteran and former CEO of Partner Colorado Credit Union, Sundie has made it her mission to normalize banking for cannabis-related business by leveraging her experience and broad industry leadership. We look forward to having Sundie's knowledge and industry perspective on the Board as we continue to expand Safe Harbor's footprint as the leading financial services provider for companies operating in the cannabis industry."

16:30 EDT Gildan Activewear provides medium-term targets - The company said, "Assuming no deterioration in the current macroeconomic environment, Gildan is confident that the targeted priorities will position the Company to continue to drive market share gains in key product categories, unlock further opportunities in targeted markets and deliver on key financial metrics over the 2025-2028 period, reflecting the following: Net sales growth at a compound annual growth rate in the mid-single digits range; Annual adjusted operating margin(1) in the range of 18% to 21%; Capital expenditures (capex) as a percentage of sales of about 5% per year, on average and adjusted diluted EPS growth per annum in the high-single to low double-digit range."

16:24 EDT Gildan Activewear CEO announces five key priorities - Gildan Activewear announced that its president and CEO, Vince Tyra has unveiled his key focus strategic priorities. Concurrently, the Company also reconfirmed its 2024 full year guidance and announced preliminary Q1 revenue. Furthermore, the Company intends to hold an Investor Day in the Fall of 2024 to provide a comprehensive strategic plan. Reflecting on his first 90 days, Vince Tyra said, "I'm excited to be leading Gildan at this pivotal time. Having completed 90 days at the helm of Gildan, I wanted to share with you my key focus strategic priorities and articulate how we can leverage our strengths and accelerate value creation for all stakeholders. Importantly, these priorities reflect feedback received from shareholders and their desire for us to continue sustainably growing Gildan. As we continue to execute on the key components of the Gildan Sustainable Growth strategy, my first few months as CEO have confirmed my belief that Gildan's core fundamentals are strong and that we are in a great position to unlock further potential and launch the next phase of our growth. My management team and I will continue to review the business and we look forward to presenting a fuller view at an Investor Day this Fall." The company commented, "With its three key pillars, Growth, Innovation, and ESG, the Gildan Sustainable Growth (GSG) strategy has set the foundation for the Company's future. Capitalizing on this strong foundation and the continued execution of the GSG plan which remains core to Gildan's business, today Vince Tyra outlined his key focus strategic priorities to unlock further growth potential while amplifying the Company's commercial capabilities. These five key priorities are: Successfully execute supply chain initiatives to maintain availability, cost leadership and industry leading margins; Leverage Gildan's unique brands and develop distinct commercial capabilities to accelerate growth and strengthen the Company's market position; Deepen Gildan's relationships with existing and prospective retail partners, strengthening the Company's position as the supplier of choice; Complement Gildan's strong North American market position with renewed focus on select international markets to drive growth; and Empower and build world-class talent and leadership to ensure long term resilience of Gildan's business."

16:18 EDT Vuzix CEO provides 2024 outlook - Vuzix CEO Paul Travers said, "Our overall outlook for 2024 remains positive. We have a good book of business with identified opportunities, representing large potential deals and cornerstone customers for our enterprise products. And on the OEM side of our business, we expect to enter into several new projects with new and existing defense and consumer product-focused customers over the course of the year. At the same time, we remain vigilant in our actions to lower our operating costs, extend our operational runway and improve our enterprise product margins. We expect our red-green-blue microLED development progress with Atomistic to accelerate over the coming year with their increased production of test samples and refinements of initial designs. We have started to engage with potential customers and development partners ranging from US and international defense organizations to a number of well-known brands and OEM supply companies. The feedback has been very positive thus far, with nearly all parties intently interested in seeing and potentially supporting Atomistic/Vuzix practical solution for MicroLEDs with high brightness, high efficiency and high contrast that should be clearly scalable and cost effective".

16:17 EDT TechnipFMC awarded large subsea contract for ExxonMobil Guyana project - TechnipFMC (FTI) has been awarded a large contract in Guyana's Stabroek Block by Exxon Mobil Corporation (XOM) affiliate ExxonMobil Guyana Limited to supply subsea production systems for the Whiptail project. TechnipFMC will provide project management, engineering, and manufacturing to deliver 48 subsea trees and associated tooling, as well as 12 manifolds and associated controls and tie-in equipment. Jonathan Landes, President, Subsea at TechnipFMC, commented: "ExxonMobil Guyana will utilize our Subsea 2.0 systems and manifolds, which help provide schedule certainty. We have already delivered more than 100 subsea trees for ExxonMobil Guyana - the location of one of the world's fastest developing basins - and we look forward to deepening our relationship with them through Whiptail." TechnipFMC currently employs nearly 140 Guyanese, and expects to continue to hire and train additional local staff in support of this award. For TechnipFMC, a "large" contract is between $500M and $1B. This award will be included in inbound orders in the second quarter of 2024.

16:16 EDT Vuzix says losses raise doubt about ability to continue as going concern - According to a regulatory filing, Vuzix said that accompanying financial statements in its Form 10-K have been prepared assuming that the company will continue as a going concern. The company noted that it has suffered recurring losses from operations and has future cash requirements to fund operating losses. This raises substantial doubt about the company's ability to continue as a going concern.

16:12 EDT Edgewise reports 'positive' two-year topline results from ARCH trial - Edgewise Therapeutics announced positive two-year topline results from the ARCH trial. ARCH is an open label, single-center study assessing safety, tolerability, impact on muscle damage biomarkers, pharmacokinetics and functional measures with sevasemten in adults with Becker. Sevasemten is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker and Duchenne muscular dystrophy. The ARCH trial evaluated sevasemten administered daily over two years in adults with Becker. Sevasemten was well-tolerated in all 12 participants with no discontinuations or dose reductions due to adverse events. Preserving NSAA functions that correlate to activities of daily living are important to individuals living with Becker. As seen in Figure 1, during two years of sevasemten treatment, participants' NSAA scores stabilized and continued to diverge relative to functional declines reported across multiple Becker natural history studies, in which two-year mean decreases of 2.4 NSAA points were reported. In addition, significant decreases in key biomarkers of muscle damage including CK and TNNI2 were observed in participants treated with sevasemten, which are consistent with prior observations. "We are pleased by the promising and consistent functional results observed over two years of treatment with sevasemten, together with the favorable safety and tolerability profile," said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Edgewise. "We thank the Becker community for engaging with us on this promising therapy."

16:11 EDT AeroVironment enters teaming agreement with Parry Labs - AeroVironment has entered into an exclusive teaming agreement with Parry Labs, a leader in Modular Open Systems Approach, to architect, develop, deliver and integrate digital engineering, software, and mission system hardware into AV's upcoming P550 uncrewed aircraft system, purpose built for the U.S. Army's Long Range Reconnaissance program. Parry Labs' team of MOSA leaders and digital systems experts have created a foundational platform using an open and intelligent software stack, SWaP-C optimized hardware, and a digital engineering environment for collaborative build, test and integration. Designed with MOSA principals from inception, AV's P550 UAS is perfectly aligned to adopt solutions from trusted partners such as Parry Labs to maximize warfighter capability and mission flexibility. "Our customers rely on AV's market-leading UAS to perform critical missions in challenging and hostile environments, while offering a verified and validated MOSA architecture from both software and hardware standpoints in order to eliminate vendor lock," said AV's Vice President of Engineering, Cris Sapera. "By teaming with Parry Labs, our valued P550 customers can expect a truly open system architecture that will have predefined Major System Components with validated open interfaces for quick, seamless replacement as needed."

16:06 EDT Skillsoft names Ronald Hovsepian executive chair - Skillsoft announced that Ronald Hovsepian has been appointed as the company's Executive Chair and will serve as principal executive officer, effective as of April 16, 2024. This appointment follows Jeffrey R. Tarr's decision to retire from his role as Chief Executive Officer and as a member of the Board of Directors, also effective April 16, 2024. To ensure a smooth transition, Tarr will serve in an advisory capacity over the coming weeks. Hovsepian has served as a Skillsoft Board member since 2018, including as Executive Chair from 2018 to 2021. In this capacity, he was instrumental in overseeing the Company's migration away from its legacy Skillport platform, accelerating the transition to Skillsoft's innovative Percipio platform, and laying the foundation for Skillsoft to become a leader in best-in-class, transformative learning experiences. Mr. Hovsepian also played a key role in strengthening the Company's operational and financial foundation, paving the way for Skillsoft to return to the public markets in 2021. "Given Ron's long history with Skillsoft and deep understanding of the business and strategy, the Board is confident he is the right person to provide continuity of leadership and guide the Company forward," said Patrick Kolek, Skillsoft's prior Chair. "Ron is a proven leader with an impressive track record, and his insights will be instrumental as we work to unlock value for Skillsoft, our stockholders and other stakeholders."

16:05 EDT Macatawa Bank trading halted, news dissemination

16:01 EDT OFS Credit estimates NAV per share of $7.42-$7.52 as of March 31 - OFS Credit Company announced the following net asset value estimate as of March 31, 2024. Management's unaudited estimate of the range of our NAV per share of the company's common stock as of March 31, 2024 is between $7.42 and $7.52. This estimate is not a comprehensive statement of our financial condition or results for the month ended March 31, 2024. This estimate did not undergo the company's typical quarter-end financial closing procedures.

15:01 EDT Appian signs Strategic Collaboration Agreement with AWS - Appian (APPN) announced that it has signed a Strategic Collaboration Agreement with Amazon Web Services (AMZN) to make generative artificial intelligence more accessible to enterprise business processes. Appian will invest significant resources to find novel ways to combine Appian's native AI capabilities and the Appian data fabric with the large language models provided by Amazon Bedrock and machine learning capabilities from Amazon SageMaker. Amazon Bedrock is a fully managed service that offers a choice of high-performing foundation models from leading AI companies via a single API, along with a broad set of capabilities organizations need to build generative AI applications with security, privacy, and responsible AI. Amazon SageMaker is a service to build, train, and deploy ML models for any use case with fully managed infrastructure, tools, and workflows.

12:39 EDT FirstEnergy's Ohio utilities reach settlement on Grid Mod II plan - FirstEnergy's Ohio electric companies - Ohio Edison, The Illuminating Company and Toledo Edison - have reached a settlement on their Grid Modernization II plan that will expand the deployment of smart meters to an additional 1.4M customers in Ohio. If approved by the Public Utilities Commission of Ohio, the four-year, $421M plan will build upon system upgrades completed as part of the companies' Grid Mod I plan approved in 2019, including installation of approximately 706,000 smart meters across Ohio along with the necessary supporting communications infrastructure and data management system. Parties to the settlement include the Citizens Utility Board of Ohio, Environmental Law & Policy Center, Interstate Gas Supply, LLC., The Kroger Co., Northeast Ohio Public Energy Council, Ohio Energy Group, Ohio Energy Leadership Council, Ohio Environmental Council, The Ohio Manufacturers' Association Energy Group, Retail Energy Supply Association and Walmart Inc.

12:09 EDT Accenture Federal Services enters agreement to acquire Cognosante - Accenture Federal Services has entered into an agreement to acquire Cognosante, a mission-driven provider of digital transformation and cloud modernization solutions for federal health, defense, intelligence, and civilian agencies. John Goodman, Accenture Federal Services CEO (Photo: Business Wire) Founded in 2008 by Michele Kang, Cognosante has grown rapidly to become a trusted provider of innovative technology solutions with its federal government clients, including healthcare programs supporting veterans, active-duty military, patients, beneficiaries, providers, and payors. The company has an exemplary delivery track record powered by technology expertise, cloud modernization and migration capabilities, and exceptional program management. Cognosante is recognized for providing great user experiences, making healthcare more accessible and equitable, and maximizing the value of federal government investments. Cognosante's team of more than 1,500 people will join Accenture Federal Services' more than 14,000 people to reimagine how work gets done, solve critical challenges, and create meaningful change. The completion of the acquisition is subject to regulatory review and other customary closing conditions. Terms of the transaction were not disclosed.

12:00 EDT Informatica falls -9.0% - Informatica is down -9.0%, or -$3.46 to $35.02.

12:00 EDT BRF S.A. rises 9.1% - BRF S.A. is up 9.1%, or 29c to $3.48.

12:00 EDT Yatsen rises 17.6% - Yatsen is up 17.6%, or 53c to $3.54.

10:14 EDT CMC Metals releases new mineralization model, selected Silverknife drill results - CMC Metal has prepared a new conceptual mineralization model for its Silverknife Property. The model is based on an interpretation of recent and historical exploration data and publicly available regional data. The model will serve as a guideline to future exploration efforts on the property and conceptually depicts the potential of the four zones on the property previously announced on March 20, 2024. In addition, selected results from the 2023 drilling at the Silverknife Prospect Area not previously announced, were as follows: Hole SKP 23-02 from a depth of 34.0 meters to 202.27 was consistently mineralized with elevated levels of zinc and lead. Of particular note is a 16.19 meter interval from 41.33-57.52 meters with an average of 11,399.3 g/t zinc with a range of values from 1,245-38,500 g/t zinc and lead values ranging from 624-11,250 g/t; a 13.65 meter interval from 83.85-97.50 meters with an average of 13,580 g/t zinc with a range of values from 2,380-34,700 g/t zinc and lead values ranging from 288-6,020 g/t a 2.70 meter interval from 125.80-128.50 m with 0.31 g/t Gold, and 59. 7 g/t Silver; and a 4.00 meter interval from 139-143.00 m with 0.20 g/t Gold, and 56.10 g/t Silver; Hole SKP 23-03 with a 1.2 meter interval from 190.30-191.50 meters with 53 g/t silver, 34,600 g/t lead, and 7,440 g/t zinc. Hole SKP 23-04 with a 1.98 meter interval from 123.40-125.38 meters with 25.02 g/t silver, 6,154.2 g/t lead, and 46,921 g/t zinc. Hole SKP 23-06: 881 g/t silver, 5,060 g/t lead, 1,500 g/t zinc and 1,335 g/t copper at a depth interval of 67.7-68.20 meters Hole SKP 2P 23-07 with a 3.91 meter interval from 72.00-75.91 m with 0.73 g/t Gold, and 17.63 g/t Silver; and a 1.6 meter interval from 172.05-173.65 meters with 9,079.7 g/t zinc; Hole SKP 23-08 with a 26.52 meter interval from70.48-97.00 meters with 2,078 g/t zinc with values ranging from 1,415-14,350 g/t and lead values ranging from 209-4,040 g/t; and, a 5.88 meter interval from 100.12-106.0 meters grading 4,224.49 g/t zinc with elevated level s of lead and zinc from 63.0-107.87 meters. Hole SKP 23-09 with a 1.0 meter interval from 55.0-56.0 meters grading 189 g/t silver, 2,680 g/t lead and 651 g/t zinc; a 1.0 meter interval from 61.0-62.0 meters grading 46 g/t silver, 1,700 g/t lead and 5,790 g/t zinc; an a 1.52 meter interval from 129.96-131.48 meters grading 67 g/t silver, 15,100 g/t lead and 4,030 g/t zinc in mineralized intervals from 55.0-72.01 meters, 93.30-96.27 meters and 123.97-134.0 meters. Fugitive calcite veining was noted in Holes SKP 23-04, SKP 23-05,SKP 23-06, SKP 23-07, SKP 23-08 and SKP 23-09. This is significant as fugitive calcite with cross-cutting "epithermal textures" suggest the presence of a large, longer life mineralizing system which is a critical factor in the formation of carbonate replacement deposits.

10:11 EDT Air Products receives funding to build two Hydrogen Refueling Stations - Air Products received funding from the Ministry of Economic Affairs, Industry, Climate Protection and Energy of the State of North Rhine-Westphalia to build two high-capacity, publicly accessible, low-carbon Hydrogen Refueling Stations in Duisburg and Meckenheim. This marks another milestone as the company continues building a European network of hydrogen refueling stations that will provide heavy duty and long-range vehicles with low-carbon energy for zero-emission fleets. The two new stations will be located near Air Products' current German headquarters in Hattingen, where Air Products has operated for more than 60 years. With the funding received, Air Products will build, own and operate the two high-capacity HRSs capable of fueling a range of vehicles including medium and heavy-duty classes. Supplied with the company's own hydrogen, the refueling stations will offer a network of reliable and fast HRSs for trucks in Germany and ultimately support the ramping up of zero-emission fleets. Funding for the stations was made available as part of NRW's hydrogen roadmap. NRW has set ambitious goals to decarbonize heavy-duty transportation and has set a target of having 11,000 hydrogen fuel cell trucks in the region by 2030. NRW also has set additional 2030 goals of having 3,800 fuel cell buses for public transportation and 200 hydrogen fueling stations.

10:02 EDT Tapestry receives European approval for Capri acquisition - Tapestry (TPR) disclosed that the and the European Commission approved its pending acquisition of Capri Holdings (CPRI) unconditionally today. At this time, the only outstanding antitrust regulatory approval or clearance for the transaction is in the United States, Tapestry added. The parties have obtained antitrust regulatory approval or clearance for the transaction in all other jurisdictions for which regulatory approval or clearance is a closing condition.

10:01 EDT L3Harris Technologies receives $256M ENVG-B production order - L3Harris Technologies received a $256M order from the U.S. Army for continued production of the Enhanced Night Vision Goggle - Binocular. This is the first order for the ENVG-B's Program of Record full-scale production IDIQ, which will total nearly $1B over 10 years.

10:00 EDT Molina Healthcare falls -5.0% - Molina Healthcare is down -5.0%, or -$18.79 to $357.78.

10:00 EDT Spirit Airlines rises 9.8% - Spirit Airlines is up 9.8%, or 41c to $4.59.

10:00 EDT Medical Properties Trust rises 22.8% - Medical Properties Trust is up 22.8%, or 91c to $4.90.

09:47 EDT Molina Healthcare falls -4.6% - Molina Healthcare is down -4.6%, or -$17.15 to $359.42.

09:47 EDT Biohaven falls -5.8% - Biohaven is down -5.8%, or -$3.08 to $50.00.

09:47 EDT Goldman Sachs rises 5.7% - Goldman Sachs is up 5.7%, or $22.21 to $411.70.

09:46 EDT Goldman Sachs says 'committed' to paying stable, growing dividend

09:42 EDT Rent the Runway trading resumes

09:38 EDT Eagle Pharmaceuticals says unlikely to file Form 10-Q or 10-K by May 13 - In a press release after the market close on Friday, Eagle Pharmaceuticals announced that it received a notice on April 8 from the Listing Qualifications Department of The Nasdaq Stock Market advising the company that due to the company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission, the company is not in compliance with Nasdaq's continued listing requirements. "The company must submit an update to the Plan by April 23, 2024, to include the company's plans to file the Form 10-K, and the company plans to include in such update that the company believes it is unlikely that it will file the Form 10-Q or the Form 10-K by the May 13, 2024, extension deadline. Pursuant to the Initial Notice, if the company fails to regain compliance prior to the expiration of such extension period, Nasdaq would provide written notification that the company's securities would be subject to delisting. However, in response to the company's updated Plan, Nasdaq may determine that the Company will not be able to become current in its filing obligations by the May 13, 2024, extension deadline and could accelerate the issuance of a delisting notice. In the event the company receives such a delisting notice, the company may request a hearing before an independent Nasdaq Hearings Panel. The hearing request would automatically stay any suspension or delisting action for 22 calendar days from the date of the delisting notification. In connection with the hearing request, the company may request that the stay be extended through the conclusion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing. There can be no assurance that any hearing would be successful, that an extended stay or additional extension would be granted, that the company will be able to regain compliance with the Rule or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules or that the company will be able to continue its listing on Nasdaq," Eagle stated.

09:24 EDT Rail Vision enters agreement with distributor for U.S. - Rail Vision entered into a non- binding memorandum of understanding with a leading railway technologies company for the distribution of Rail Vision's MainLine and ShuntingYard products. On March 18, 2023, the Company revealed its intention to broaden its sales operations in the US by collaborating with a top distributor to promote its unique products. Furthermore, Rail Vision aims to solidify its standing as a premier provider of safety products by directly engaging with and selling to industry leaders, Class I railroad companies, and top-tier players within the US railway sector. The distributor develops leading engineering, science and advanced technological solutions for passenger, transit and freight rail markets for governments and private entities worldwide. Upon the execution of definitive documentation, the ultimate objective of this engagement is for the distributor to market the Company's solutions across North America.

09:21 EDT Blackbaud confirms unsolicited buyout proposal from Clearlake Capital Group - Blackbaud confirmed that it has received an unsolicited, non-binding proposal from Clearlake Capital Group, a current stockholder of the company, to acquire all of the outstanding shares of Blackbaud for $80.00 per share in cash. Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Blackbaud Board of Directors will carefully evaluate the proposal to determine the course of action that it believes is in the best interest of the company and all Blackbaud stockholders

09:15 EDT Sealsq launches R&D projects blending IoT with cryptocurrency mining - SEALSQ Corp unveiled its innovative R&D projects blending IoT with cryptocurrency mining for the development of new, more energy-efficient mining algorithms that are tailored specifically for IoT devices. The deployment of this project will enable IoT devices to not only mine cryptocurrencies but also to process transactions directly, leveraging their operational downtime. This forward-thinking project is poised to transform everyday electronic devices into active participants in the cryptocurrency market, creating additional value and utility.

09:12 EDT Kratos Defense completes development of Zeus Solid Rocket Motor family - Kratos Defense & Security Solutions (KTOS) announced that its Space & Missile Defense Systems, SMDS, Business Unit, a part of Kratos' Defense & Rocket Support Services, DRSS, Division, successfully completed the static test firing of the Zeus 2 solid rocket motor, SRM, with Aerojet Rocketdyne, an L3Harris Technologies (LHX) company, at their Camden, Arkansas facility. This Zeus 2 milestone combined with the successful Zeus 1 static test firing last year, completes the development phase of Kratos' new affordable commercial SRM family.

09:11 EDT Gorilla, Lanner launch new line of Security Convergence Devices - Gorilla Technology Group introduced its new line of Security Convergence Devices, developed in collaboration with Lanner. These hardware appliances lead the market in innovation and efficiency and epitomize Gorilla's commitment to safeguarding digital perimeters with unparalleled efficacy and cost-effectiveness. Dr. Rajesh Natarajan, Chief Technology Officer at Gorilla Technology, commented, "We are proud to introduce these Security Convergence Devices, which usher in a revolutionary era in cybersecurity. In this product line, the prowess of artificial intelligence melds flawlessly with cutting-edge hardware, setting a new benchmark for protection. With NetProbe steering the course, we are arming enterprises with the means to identify and counteract cyber threats and the strategic advantage to outpace them."

09:09 EDT La Rosa Holdings signs six-month media deal with New to the Street - FMW Media Inc.'s New to The Street announces signing La Rosa Holdings to a six-month media contract that will feature the Company on show's televised sponsored programming. Joe La Rosa, Founder and CEO of La Rosa Holdings Corp., states, "I'm excited to have La Rosa Holdings Corp. featured on New to The Street's main business show and forthcoming appearances on the show's IPOMarket segment. The New to The Street audience can learn more about our Company's five agent-centric, technology-integrated, cloud-based, multi-service real estate segments. As a new publicly traded company on NASDAQ, we are thrilled to highlight how La Rosa Holdings is at the forefront of transforming the real estate industry. With our focus on defining what is true Agent Centricity and transparency, we are shaping the future of real estate by bringing clarity and empowerment to every transaction and by providing Agents the financial flexibility they need in today's new market."

09:08 EDT WalkMe announces major proof points of continuing category leadership - WalkMe announced major proof points of its continuing category leadership, as digital adoption platforms gain rapid momentum in a $34B total addressable market. Achievements include a bold array of AI-centric product innovations and patents, analyst and industry recognition, superior customer service reviews, category-defining thought leadership, and continued financial growth. WalkMe recently announced that its annual flagship event, Realize, will be held on June 18, 2024, where the company will unveil more exciting product advancements to decisively shape the future of AI in the workplace.

09:07 EDT Kartoon Studios partners with VeVe to produce limit-edition collectibles - Kartoon Studios, the controlling partner of "Stan Lee Universe, LLC," partners with VeVe to produce a series of limited-edition Stan Lee digital and physical collectibles to be included in launches aimed for June and July around San Diego Comic-Con.

09:05 EDT AIM ImmunoTech appoints Lapp as a consulting Medical Officer - AIM ImmunoTech announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome and Long COVID. Dr. Lapp has played a key role in AIM's long-standing AMP-511 Expanded Access Program for the treatment of ME/CFS and Long COVID, having founded one of the clinical trial's key sites, the Hunter-Hopkins Center in Charlotte, N.C., from which he recently retired.

09:03 EDT Castor Maritime announces compliance with Nasdaq minimum bid price requirement - Castor Maritime announces that it received a written confirmation from The Nasdaq Stock Market LLC on April 11, 2024, that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price of the Company's stock.

09:02 EDT DiamondRock announces leadership changes - DiamondRock Hospitality announced leadership changes and a simplified organizational structure to drive continued business momentum: Jeffrey Donnelly, previously Executive Vice President and CFO, has been appointed CEO. Donnelly is expected to join the Company's Board of Directors after the 2024 Annual Meeting of Stockholders, which will be held in May. He succeeds Mark Brugger, who, after 20 years of service, is departing the Company. Briony Quinn, previously Senior Vice President and Treasurer, has been named Executive Vice President, CFO and Treasurer, succeeding Donnelly. Justin Leonard, formerly Executive Vice President and COO, has been appointed President. Leonard will maintain his role as COO and will assume the responsibilities previously overseen by Troy Furbay, Executive Vice President and Chief Investment Officer, who is departing the Company. With these changes, which are effective today, DiamondRock has reduced its executive team structure from six to four members, including the Company's Executive Vice President and General Counsel.

08:47 EDT Sigma Lithium begins loading of 22,000 tonnes of high-purity lithium concentrate - Sigma Lithium announces it has commenced the on-time loading of its eighth shipment of quintuple zero green high-purity coarse lithium concentrate, totaling 22,000 tonnes, at the Port of Vitoria. The achieved price is final and non-provisional and represents a meaningful increase over the previous premium prices achieved. As a reference, the final price net of VAT is equivalent to 8.75% of the LME Lithium Hydroxide CIF market price, as previously disclosed in a news release on March 27, 2024. 85% of the eighth shipment's value has also been prepaid.

08:43 EDT Tharimmune establishes Scientific Advisory Board - Tharimmune announced the formation of a new Scientific Advisory Board that includes a group of leading experts in fields spanning immunology, liver disease clinical trials, protein engineering, antibody drug conjugates as well as Knob domains, the smallest antibody like fragments. Tharimmune's lead clinical-stage asset, TH104, is designed as an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions, by avoiding the first-pass metabolism usually in traditional oral formulations and designed for studying cholestatic conditions. The SAB's collaboration will drive our clinical-stage asset, TH104 in patients with moderate-to-severe chronic pruritis associated with primary biliary cholangitis with a planned Phase 2 study in 2024 and help identify future areas of interest and development for the novel platform and includes: Andreas Kremer, MD, PhD is Clinician Scientist and Professor of Hepatology in Zurich and lead investigator for multiple clinical trials whose expertise spans autoimmune and cholestatic liver disease, liver fibrosis, hepato- and cholangiocellular carcinoma, the gut-liver-axis and has high expertise in pruritus and fatigue. Alan Bonder, MD, AGAF is Associate Professor of Medicine at Harvard University Medical School and Medical Director of Liver Transplant at Beth Israel Deaconess Medical Center in Boston; his expertise spans chronic liver diseases including cholestatic liver diseases including PBC and non-cholestatic liver diseases with expertise in patient care, clinical trials and pruritis associated with these conditions. The Company is also advancing novel antibodies in bovine animals or cows and derived from ultra-long complementary determining region 3 domains which potentially enable access to epitopes that had previously been hidden or highly inaccessible in traditional antibody development. With a much smaller size compared to traditional antibodies, combined with structural diversity, Knobs can bind to conformational, linear or discontinuous epitopes in "undruggable" areas of validated targets. They are derived from bovines, which unlike other species, express ultralong CDR-H3 regions forming an independently folding mini-domain, which protrudes far out from the surface of the antibody and is diverse in both its sequence and disulfide patterns. These atypical antigen binding sites of bovines potentially provide the ability to interact with different antigenic determinants capable of eliciting an immune response, particularly recessed or concave surfaces, compared to traditional antibodies. This conceivable "multi-specific" capacity of Knobs, are the basis of developing Tharimmune's early-stage pipeline including ADCs and may more efficiently target multiple cell surface portions compared to known or existing biologics. The SAB will collaborate with Tharimmune to develop next generation antibody, Knob domain and ADC platforms and includes: John Lambert, PhD is one of the leading experts in the field of ADC discovery and development. Vaughn Smider, MD, PhD is the founder and President of the Applied Biomedical Science Institute and is an adjunct Professor at the Scripps Research Institute.. The Company previously announced sufficient funding to extend its cash runway into early 2025 for a phase 2 clinical readout of its lead program, TH104. Tharimmune plans to advance both its clinical and non-clinical programs and will announce an R&D update in 2024.

08:41 EDT ContextLogic urges stockholders to vote for Qoo10 transaction - ContextLogic mailed a letter to stockholders in connection with its upcoming Special Meeting of Stockholders urging stockholders to vote "FOR" the proposed transaction with Qoo10. The Special Meeting is scheduled to be held at 11:30 a.m. Pacific Time on April 18, 2024. Stockholders of record as of March 7, 2024, are entitled to vote. The letter read in part, "We have set a new date and time of Thursday, April 18, 2024, at 11:30 a.m. Pacific Time, to hold our Special Meeting of Stockholders to approve the proposed Asset Sale transaction with Qoo10 Pte. Ltd. AS OF APRIL 12TH, LESS THAN 350,000 SHARES WERE NEEDED TO VOTE "FOR" THE ASSET SALE IN ORDER FOR THE TRANSACTION TO BE APPROVED We are urging all ContextLogic stockholders, regardless of the amount of shares you own, to vote "FOR" the transaction TODAY. The holders of a majority of ContextLogic's outstanding shares must vote in support of the transaction for it to be completed."

08:39 EDT REV Group appoints Amy Campbell as CFO - REV Group announced Amy Campbell has joined the company as CFO, effective immediately. Campbell sits on REV's executive leadership team and reports to CEO and president Mark Skonieczny. Prior to REV Group, Campbell served as CFO of ASC Engineered Solutions and CFO for BrandSafway's Commercial and Industrial Division.

08:38 EDT 3D Systems announces FDA clearance for 3-D printed PEEK cranial implants - 3D Systems announced the Food and Drug Administration, FDA, has provided 510(k) clearance for its 3D-printed, patient-specific cranial implant solution - VSP PEEK Cranial Implant. VSP PEEK Cranial Implant includes a complete FDA-cleared workflow comprising segmentation and 3D modeling software, the 3D Systems EXT 220 MED 3D printer, Evonik VESTAKEEP i4 3DF PEEK, and a pre-defined production process. "3D-printed PEEK cranial plates are an innovative solution that can improve patient care and expand the possibilities for precise, individualized neurosurgery," said Dr. Johannes Poppe, senior attending surgeon, department of neurosurgery, University Hospital Salzburg. "The solution is revolutionizing the field. The combination of 3D Systems' printing technology that is uniquely engineered for sterile environments along with the mechanical properties of PEEK are helping surgeons push boundaries. Within our hospital, we have already completed several successful surgeries using these technologies. I believe the potential for customized PEEK cranial plates is significant to integrate 3D printing into routine clinical practice."

08:37 EDT IceCure Medical submitts data to FDA for marketing authorization of ProSense - IceCure Medical announced that it has submitted final data to the FDA requesting marketing authorization for ProSense for the indication of treating patients with early stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy. ProSense, which received the FDA's Breakthrough Designation, is already cleared for use in the U.S. for several other indications, including treating benign tumors of the breast, and tumors in the kidney and liver. The Company provided the following requested data to the FDA: ICE3 5-year follow up full data-set; sub-analysis of the ICE3 results compared with data from the "LUMINA" study; analysis of the ICE3 data compared to an updated PRISMA meta-analysis; and real-world data from the use of ProSense globally, including post-market commercial use as well as data from independent third-party studies. The ICE3 study was the largest controlled multicenter clinical trial ever performed for liquid nitrogen based cryoablation of low-risk, early-stage malignant breast tumors.

08:37 EDT IperionX partners with United Stars for U.S. sourced titanium manufacturing - IperionX Limited has signed a framework agreement with United Stars Holdings with terms that will underpin a definitive commercial supply agreement for IperionX's titanium products. United Stars expects to purchase up to 80 metric tons annually of IperionX's high-performance, low cost and sustainable titanium products over a 10-year supply term...IperionX and United Stars have signed a non-exclusive framework agreement to underpin the terms for a definitive titanium supply agreement, which the parties have agreed to work together in good faith to prepare and negotiate. The definitive titanium supply agreement is expected to include the sale and purchase of the lesser of 40% of IperionX's Phase 1 titanium production capacity, or eighty metric tons per annum of IperionX's angular titanium powder and consolidated titanium products, for a ten year term. Final pricing and payment terms will be agreed under the definitive supply agreement. The Framework Agreement is effective from April 12 until the execution of the definitive titanium supply agreement and can be cancelled by IperionX or United Stars with 60 days written notice.

08:35 EDT Reviva Pharmaceuticals announces FDA alignment on brilaroxazine trial - Reviva Pharmaceuticals Holdings announced it has gained alignment with the U.S. Food and Drug Administration, FDA, on its registrational Phase 3 program for brilaroxazine in schizophrenia. The FDA accepted a 4-week RECOVER-2 study for brilaroxazine in schizophrenia. Notably, the FDA also indicated that two positive Phase 3 studies showing efficacy at week 4 that are accompanied by long-term safety data of at least 12 months could be supportive of an NDA submission for the acute treatment of schizophrenia. "We are pleased to receive positive feedback from the FDA and acceptance of a 4-week registrational study for our brilaroxazine program," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "The FDA also clarified that our NDA submission could include two 4-week phase 3 studies showing efficacy and a 12-month long-term safety study. Importantly, we have already successfully completed and announced the results of our pivotal Phase 3 RECOVER trial in October 2023, and we are set to initiate our RECOVER-2 trial during this quarter. We expect topline data from our 1-year OLE trial in the fourth quarter of this year. Collectively, we expect to have completed all of the outlined NDA submission requirements by the third quarter of 2025."

08:34 EDT Ituran pushes its forward-looking yield to 6% after strong Q4 - Ituran Location and Control added $8M to its dividend pool after a strong Q4, pushing its forward-looking yield to 6%. That attractive yield comes after the company posted record across-the-board financial metrics, including a 9% revenue increase year-over-year to $320M, net income of $48M, an increase of 30% year-over-year, and a 10% increase in EBITDA to $87M. As of last Friday's close, ITRN's market cap is about $521M. That performance helped generate a bullish price target from an analyst at Barclay's, who models that Ituran shares could touch $35 within the next twelve months, an over 33% increase from current levels. That model likely factors in record revenues and the company generating $77M in FY2023 operating cash flow, resulting from a string of deals from global companies interested in its revolutionary telematics and connected car ecosystem.

08:34 EDT Beacon announces acquisition of General Siding Supply - Beacon announced that it has completed the acquisition of General Siding Supply headquartered at its Omaha, NE branch, with four additional branches located in Lincoln, NE, Grand Island, NE, Sioux City, IA and West Fargo, ND. "This acquisition deepens our complementary building product offering and adds branch locations that expand our branch network in key markets. The Spanheimer family's business has a long-standing reputation as siding specialists with unparalleled technical knowledge and service reliability. We are proud to have them join Team Beacon," added Bill Sarvis, Beacon's Regional Vice President, Midwest. Beacon has completed three acquisitions adding twelve branches and signed a purchase agreement for a fourth acquisition to date in 2024. In addition, five new locations have opened this year. Footprint expansion is an important element of our Ambition 2025 plan. We continue to deliver on our commitments to drive above-market growth to better serve customers. The company exceeded its Ambition 2025 revenue and shareholder return targets two years early and continues to make significant advances to achieve the full Ambition 2025 plan.

08:34 EDT Microbot says activities continue without interruption amid geopolitical events - Microbot Medical shared that despite the unprecedented events in Israel yesterday, which are a continuation to the situation in Israel since October 7th, 2023, the Company's activities both in Israel, USA and other parts of the globe continue without interruption and it believes that current planned timelines and milestones will be met. From a regulatory perspective, the Company has been working with the FDA on its recent IDE submission and believes that those efforts will result in commencing its pivotal study in humans as planned. In addition, as part of its efforts to gain regulatory approval in Europe, the Company successfully completed an internal audit in preparation for ISO 13485 certification audits, which are expected this year, to ensure the Company continues to meet its timeline toward CE approval. From an operational perspective, the Company has established sufficient inventory of the LIBERTY Endovascular Robotic Surgical System to support its pivotal study and other ongoing activities. In addition to focusing on gaining regulatory approval for the current LIBERTY Endovascular Robotic Surgical System in both the USA and Europe, the Company already executed an initial phase partnership with one clinical partner and is in advanced discussions with additional clinical partners to develop the future potential capabilities of the LIBERTY Endovascular Robotic Surgical System, such as remote operations, imaging integration and AI capabilities. With its pre-commercial activities, the Company is already in discussions with multiple strategic partners, both in the USA and globally, to allow the Company to evaluate the most efficient commercialization channels once the product would be approved for sale in the USA and globally.

08:31 EDT SpartanNash acquires Metcalfe's Market chain in Wisconsin - SpartanNash announced its acquisition of Metcalfe's Market, a three-store grocery chain in Wisconsin. Upon close of the sale, the Madison and Wauwatosa, Wis. locations will be continuing employment for all employees. The Metcalfe's Market storefront, branding and core shopper experience will remain in place. Metcalfe's Market is a community staple, specializing in premium quality foods, sustainability practices, and an extensive focus on local products featuring Metcalfe's Food Miles program. Former owners Tim and Kevin Metcalfe - the great-grandsons of Metcalfe's Market founders - will join the SpartanNash family of Associates. Metcalfe's Market will expand SpartanNash's footprint in Wisconsin to seven stores. As part of the acquisition, full-time Metcalfe's Market team members will continue to receive a benefits package featuring a variety of medical, vision and dental plans, as well as additional investments in paid time off, wellness perks, tuition reimbursement and more. The transaction is expected to be completed in spring 2024, subject to customary closing conditions. Terms of the deal were not disclosed.

08:25 EDT BioLargo says PFAS removal technology meets U.S. drinking water standards - BioLargo, confirmed that its Aqueous Electrostatic Concentrator can remove per- and polyfluoroalkyl substances from water to meet and surpass the U.S. Environmental Protection Agency drinking water limits for PFAS chemicals announced April 10, 2024. Additionally, the AEC produces far less PFAS-laden solid waste than carbon filtration or ion exchange, which should result in lower long-term costs for customers while reducing potential regulatory burden. BioLargo also offers advisory services, analytical testing, and education on PFAS science and regulations to water providers who need assistance complying with the new regulations. The newly finalized rules set national limits for PFAS in public drinking water to nearly undetectable levels, as low as 4 parts per trillion.

08:22 EDT Reunion Gold announces additional drill results from Oko West project - Reunion Gold announced additional drill results from its infill drill program on Block 6 at its 100%-owned Oko West Project in Guyana. These results continue to expand the core of high-grade mineralization that has been identified at Block 6 and are consistent with the results of the previously released hole D-380, which intersected 39.7 meters at 5.27 grams per tonne of gold including 3.8 m @ 14.18 g/t Au and 13.0 m @ 10.50 g/t Au. Rick Howes, CEO of Reunion Gold, stated, "We are pleased to see the identification of further high-grade mineralized shoots at Oko West, resulting from the exploration team's growing understanding of structural controls and the factors that are localizing mineralization along the Kartuni shear zone. These latest results continue to indicate the potential for additional high-grade gold mineralization to be defined even within areas of existing wider drill spacing as our current infill program continues." Highlights of drill results reported include Hole D-375, which intersecting 60.4 m grading 1.50 g/t Au, including 6.0 m grading 7.06 g/t starting at 31.5 m downhole, Hole D-381 intersecting 44.9 m grading 2.28 g/t Au starting at 85.2 m downhole, including 18.3 m grading 4.38 g/t Au, as well as Hole D-389, intersecting 21.6 m grading 4.00 g/t Au starting at 150.0 m downhole, including 4.0 m grading 17.67 g/t Au. The Company continues to conduct its drill program designed to both expand and infill the Oko West resource, as well as to advance its exploration programs to identify additional areas of mineralization outside of the resource area at Oko West. In parallel with this, the Company continues to move its development studies forward, with the near-term goal of releasing a Preliminary Economic Assessment by the end of Q2 2024.

08:19 EDT KULR Technology announces appointment of Grier to board - KULR Technology Group announced the appointment of new independent director, Donna Grier, to the Company's Board of Directors. Grier will serve as Chair of the Audit Committee and a member of both the Nominating and Corporate Governance and Compensation Committees of the Board. Concurrently with the appointment of Grier, current director Morio Kurosaki will retire from the Board effective immediately.

08:17 EDT Microchip acquires Neuronix AI Labs, terms not disclosed - Microchip has acquired Neuronix AI Labs to expand its capabilities for power-efficient, AI-enabled edge solutions deployed on field programmable gate arrays. Neuronix AI Labs provides neural network sparsity optimization technology that enables a reduction in power, size and calculations for tasks such as image classification, object detection and semantic segmentation, while maintaining high accuracy. Microchip's mid-range PolarFire FPGAs and SoCs already lead the industry in terms of low power consumption, reliability and security capabilities. The acquisition of this technology will enable Microchip to develop cost-effective, large-scale edge deployments of components designed for use in computer-vision applications on systems that have cost, size and power constraints and enable a multifold increase in AI/ML processing horsepower on low and mid-range FPGAs. The acquisition of this technology will allow non-FPGA designers to harness powerful parallel processing capabilities using industry-standard AI frameworks without requiring in-depth knowledge of FPGA design flow. The combination of Neuronix AI intellectual property and Microchip's existing compilers and software design kits allows for AI/ML algorithms to be implemented on customizable FPGA logic without a need for resistor-transition level expertise or intimate knowledge of the underlying FPGA fabric. It is also designed to allow for updating and upgrading CNNs on the fly without needing to reprogram hardware.

08:15 EDT Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial - Viracta Therapeutics reported positive topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma cohort. These data were featured in an oral presentation during the 2024 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan. Key takeaways from the pivotal Phase 2 NAVAL-1 trial in patients with R/R EBV+ PTCL: Nana-val demonstrated greater efficacy than nanatinostat monotherapy and was generally well-tolerated. The median duration of response continues to mature. Overview: A total of 20 patients with primarily Stage III-IV disease were randomized to receive nanatinostat alone or as Nana-val in combination with valganciclovir. Patients who did not respond to nanatinostat monotherapy after 6 weeks of treatment were offered the opportunity to cross over to receive Nana-val. Efficacy was evaluated as of the February 7, 2024 data cutoff date. In the Nana-val arm, the overall response rate was 50% and the complete response rate was 20% in the intent-to-treat population; the ORR was 71% and the CRR was 29% in the efficacy-evaluable population. In the nanatinostat monotherapy arm, the ORR and CRR were 10% and 0%, respectively, in the ITT population, and the ORR was 13% in the efficacy-evaluable population. Five nanatinostat monotherapy patients crossed over to receive Nana-val, two of whom remain on Nana-val treatment with stable disease as of the data cutoff. Safety was also evaluated as of the February 7, 2024 data cutoff date. The most common treatment-related adverse events in both treatment arms were thrombocytopenia, anemia, fatigue, decreased appetite, nausea, diarrhea, and weight loss. These adverse events were primarily mild to moderate in severity and generally manageable or reversible

08:13 EDT NV5 Global expands strategic collaboration with Cadence Design Systems - NV5 Global announced a strategic collaboration with Cadence Design Systems to qualify, design, and demonstrate ideal data center design conditions for AI data center platforms, including NVIDIA AI Compute systems. The intent of the collaboration is to develop the optimal data center environment for the fastest and most reliable data center hardware and software performance. "NV5's data center engineering and commissioning business continues to expand domestically and internationally, and we are pleased to contribute to this collaboration in the rapidly evolving AI data center industry," said Dickerson Wright, Executive Chairman of NV5. "We look forward to our continued partnership as we work to design optimized data center environments that meet demands for ever-expanding computing capacity and speed."

08:12 EDT NeoGames partners with BIG Brazil for Caesars Brazil brand - NeoGames has signed a deal with BIG Brazil to power the operator's entry into the country's newly regulated iGaming market with its Caesars Brazil brand. As part of the deal, NeoGames' launch with BIG Brazil will encompass its industry-leading gaming platform, sportsbook solution, online games and additional operational products and services, as the Company embarks on its mission to become a leading supplier in the soon to be regulated Brazilian market, a market that has the potential to become one of the largest in the world. Tsachi Maimon, President and Head of iGaming at NeoGames, said: "Over the past 2 years we have become closely acquainted with the BIG Brazil team and have learned firsthand of their ambitious plans for the Brazilian market. We are excited to have been selected as their supplier and to have the privilege of supporting them in their journey to become the leading operator in the Brazilian market."

08:11 EDT Gorilla announces 1 for 10 reverse stock split - Gorilla Technology Group announced on April 9, 2024 that it will implement a 1-for-10 reverse stock split of its shares, effective April 15, 2024. The reverse split it is intended to regain compliance with Nasdaq's minimum bid price requirement before the May 1, 2024 deadline. Jay Chandan, CEO of Gorilla, commented, "Despite our robust financial performance in 2023 and a very strong pipeline for 2024, the present market valuation of our shares does not fully capture Gorilla's intrinsic value. We are proactively addressing these market challenges, utilizing our commitment to innovation, operational excellence, and unwavering customer satisfaction to solidify our leadership in the industry. We deeply appreciate the relentless support from our employees, investors, and board members. This reverse stock split is a key component of our comprehensive strategy designed to fortify Gorilla's resilience and drive our ongoing success."

08:11 EDT Agilent gets European IVDR certification for GenetiSure Dx postnatal assay - Agilent Technologies announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the higher standards established by IVDR. It ensures the continued availability of this trusted qualitative assay to clinical geneticists and other healthcare professionals throughout the EU. In vitro diagnostic devices, which include pregnancy tests, COVID-19 tests, urine test strips, and more, are estimated to play a part in 70% of all diagnostic decisions. The EU has introduced the IVDR regulatory framework to ensure the safety and performance of these devices. Under the new rules, in vitro diagnostic devices are subject to more stringent regulatory scrutiny to ensure rigorous standards of clinical evidence are met, with greater transparency and tighter standardization. The GenetiSure Dx Postnatal Assay uses Agilent's proprietary array Comparative Genomic Hybridization, aCGH, to identify copy-number and copy-neutral changes across the genome, enabling cytogeneticists to accurately assess genetic anomalies associated with developmental delay, intellectual disability, congenital anomalies, and dysmorphic features. The assay is based on chromosomal microarray technology with a firmly established track record of diagnostic accuracy and ease of use. Bob McMahon, interim president of Agilent's Diagnostics and Genomics Group, commented on this announcement. "The GenetiSure Dx Postnatal Assay will advance the postnatal diagnosis of chromosomal abnormalities, as it combines high resolution, accuracy, and speed in a single test. With the European IVDR Class C Certification, we are confident that this assay will continue to serve the needs of healthcare professionals and their patients across the EU."

08:09 EDT ACV Transportation expands services to vehicles purchased outside its platform - ACV continues to support the evolving transportation service needs of its customers and partners. Recently, the company announced that ACV Transportation has expanded its services to include vehicles that were not purchased on the ACV platform. ACV is accelerating its technology investment in 2024 to deliver even smoother customer experiences related to transportation.

08:08 EDT Organovo announces Phase 2 results for FXR314 - Organovo Holding released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis, MASH. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. Study subjects receiving FXR314 achieved statistically significant reduction in liver fat content from baseline, with LS mean percent reduction at end of treatment of 22.8% with 3 mg and 17.5% with 6 mg doses of FXR314 compared to 6.1% in the placebo group. The proportion of subjects with greater than30% magnetic resonance imaging-derived proton density fat fraction reduction was 29.2% and 32.2% for 3 mg and 6 mg FXR314, respectively, compared to 9.5% with placebo. Investigators observed improvements in hepatocellular damage and liver function based on serological measures, with no evidence of worsening of liver fibrosis. FXR314 was also found to be safe and well tolerated.

08:07 EDT UroGen Pharma announces FDA acceptance of UGM-103 IND - UroGen Pharma announced the FDA accepted the company's investigational new drug, or IND, application for UGN-103, a next-generation novel mitomycin-based formulation for low-grade intermediate-risk non-muscle invasive bladder cancer.

08:06 EDT Verses Technologies provides Q1 corporate update - "For an early-stage company we have so much going on, especially in the last few months. We wanted to provide this update to share our progress," said Gabriel Rene, founder and CEO of VERSES. The company said, "In the Company update last year, VERSES announced the merger of many of their previous technologies and applications into a single developer platform and data pipeline called Genius to enable developers to develop and deploy intelligent agents. VERSES launched their Genius Private Beta program in October 2023 to enable early access to partners across multiple industries to showcase the applicability of Genius. To date, the Company has announced the following 6 Beta engagements: Nalantis, Cortical Labs, SimWell, NASA's Jet Propulsion Laboratory, Volvo Cars, and Blue Yonder. Additionally, VERSES has received over 3,700 sign ups for the limited private preview of its Genius Public Beta program. Commercial Engagements/Projects VERSES entered into an agreement last year with a national US pharmacy retailer to enhance the retailer's operational intelligence and the efficiency of its existing and newly designed distribution centers. On January 18th, VERSES announced its partnership with Analog in connection with potential smart city projects in Abu Dhabi. R&D/Benchmarks On Feb 22nd, 2024, VERSES released a research roadmap that outlines its key milestones and benchmarks against which to measure the progress and significance of the Company's research and development efforts against conventional deep learning. Spatial Web Protocol, Architecture and Governance Standards On Friday, April 12th, the Company announced the progress of the Standard for Spatial Web Protocol, Architecture and Governance moving to the final balloting process at the Institute of Electrical and Electronics Engineers. IP VERSES has 11 patent applications currently pending. 10 are provisional and filed in the USA, but the Company also has one International application that is currently in the "National Phase." The Company also has 14 registered trademarks plus another 9 applications currently pending in the USA, Europe and Australia. VERSES also claims a variety of trade secrets and various copyrights in software and other original works of authorship."

08:04 EDT G2 Goldfields provides update for exploration program at OKO-AREMU project - G2 Goldfields provides an update on the ongoing exploration program at the Company's 27,719 acre OKO-AREMU gold project. G2 recently announced an updated Mineral Resource Estimate for the OKO-Aremu Project comprised of 922,000 ounces of gold and 1,099,000 ounces of gold. The entirety of the reported gold resource lies within 500 meters of surface and contains a high grade core of 688,000 ounces Au at 9.03 g/t Au and 495,000 ounces Au at 6.38 g/t Au at the OKO MAIN ZONE. Recent drill results confirm the prospectivity of the area between the high grade OMZ resource and Ghanie open pit area, approximately 1 km to the south. The Ghanie Resource currently hosts 236,000 ounces Au and 604,000 ounces Au. Since February, G2 has completed an additional twenty drill holesat Ghanie, for a total of 124 holes totalling 25,520 meters to date in the greater Ghanie area. Results from an additional five holes are reported herein and continue to establish significant widths of gold mineralization in the lower part of the Ghanie Central area. Highlights include 24m @ 2.9 g/t Au including 3.0m @ 7.0 g/t Au as well as 10.5m @ 4.5 g/t Au including 4.5m @ 6.7 g/t Au. A complete table of results is available here. At the Ghanie North area, hole GDD-93 returned 24.5m @ 5.3 g/t Au. This intercept lies within a relatively unexplored 1 km long section of the Oko structure that is currently being drilled by G2. Near surface drilling results from the 2023 program include 36.2m @ 0.9 g/t Au, 45.9m @ 0.9 g/t Au and 27m @ 1.2 g/t Au as well as 1.5m @ 69.3 g/t Au and 1.5m @ 45.6 g/t Au. Current drilling has intercepted visible gold (VG) in two holes well outside the current geological model. Assays are pending from a further fifteen holes in the Ghanie district.

08:03 EDT EQT announces agreement with Equinor to sell interest in assets in Pennsylvania - EQT announced it has entered into an agreement with Equinor USA Onshore Properties and their affiliates to sell an undivided 40% interest in its non-operated natural gas assets in Northeast Pennsylvania, representing approximately 225 MMcf/d of forecasted 2025 net production. Consideration for the transaction is comprised of $500M of cash and upstream and midstream assets as described below. Based on recent strip pricing, EQT forecasts aggregate 2025 free cash flow of approximately $75M from the non-cash consideration. The assets EQT is receiving in the transaction consist of: 26,000 net acres in Monroe County, Ohio with 2025E net production of ~135 MMcfe/d directly offsetting EQT-operated acreage; 10,000 net acres in Lycoming County, Pennsylvania with 2025E net production of 15 MMcfe/d in existing EQT-operated assets; the remaining 16.25% ownership in EQT-operated gathering systems servicing core operated acreage in Lycoming County, Pennsylvania; a gas buy-back agreement whereby Equinor will purchase gas from EQT at a premium to in-basin pricing through the Q1 of 2028. The transaction is subject to customary closing adjustments, required regulatory approvals and clearances, and is expected to close in late second quarter of 2024. EQT expects no cash tax leakage associated with the transaction.

07:49 EDT Biomerica provides update on inFoods IBS expansion - Biomerica announced advancements in the roll out of the inFoods IBS product. Biomerica has expanded its reach with adoption by new offices in targeted regions, including the Southeast, Northeast and Midwest. The Company's new salesforce has activated over 30 new Gastrointestinal physician groups, each with multiple GI physicians, and these new practices have begun recommending the Company's revolutionary inFoods IBS Product to their IBS patients. Furthermore, the average increase in the number of physicians prescribing inFoods more than doubled each quarter over the past 12 months, reflecting growing adoption and trust within the GI medical community. The Company is also in discussions with large non-GI physician groups for utilization of the inFoods IBS test. This advances the strategic effort to expand to non-GI physicians to provide cutting-edge non-pharmaceutical care options for individuals grappling with chronic IBS conditions. This continued expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for irritable bowel syndrome while positioning the Company for product revenue growth over the coming quarters. Biomerica has also been issued notices of allowance on five new patents in Japan, Canada and the EU, for a total of 25 pending/issued patents worldwide. These allowed/issued patents cover the Company's inFoods Technology and validate the novelty of this technology.

07:43 EDT Alta Global partners with Rafael Cordeiro for MMA training for UFC fans - Alta Global Group announced that Kings MMA Founder and esteemed coach Rafael Cordeiro will join the Alta Academy. Cordeiro, who is currently training former World Heavyweight Champion Mike Tyson for his much-anticipated upcoming bout with Jake Paul on July 20, broadcast exclusively on Netflix, brings a wealth of experience to the Alta Academy platform.

07:40 EDT Avant Brands reports strategic priorities for 2024 - The company said, "1. Market Expansion and International Growth: Avant Brands recognizes the immense potential of international cannabis markets. Leveraging our brand reputation and quality recognition, the Company will prioritize the following strategic initiatives for the remainder of fiscal 2024: Target High-Potential Markets: From Germany's recent legalization to emerging markets, Avant will strategically expand its global reach. Secure Additional Clients: As one of Canada's largest indoor producers, the Company is well-positioned to continue expanding its international sales and actively seek partnerships in the UK, Switzerland, and other emerging markets. 2. BLK MKT: Building a Global Icon. The Company's flagship brand, BLK MKT, is well-positioned for global recognition. Key initiatives to support this include: Strategic Licensing Partnerships: With a priority to expand BLK MKT beyond Israel and Germany, the Company is in active discussions to launch the BLK MKT brand in Australia, solidifying its status as a premium cannabis icon. 3. Revenue Growth and Strong Partnerships: Avant Brands remains committed to strong international partnerships: Successful Deliveries: Initial shipments to a new international client are complete, reinforcing our commitment to reliability. Repeat Business: Avant anticipates continued shipments as we continue building trust and reliability amongst new and existing clients. 4. Driving Efficiency and Quality for Sustainable Growth: Efficiency and quality are the cornerstones of Avant's operations. This commitment is evident in our recent achievements: Increased Production & Reduced Costs: Avant expanded its production capacity by 50% through the Flowr acquisition while simultaneously achieving a 14% reduction in SG&A and corporate overhead. This demonstrates effective cost-control strategies that support sustainable growth. Quality at Scale: As we scale our global footprint, maintaining the highest quality standards remains paramount. 5. Driving Canadian Recreational Sales: Avant Brands is committed to capturing a significant share of the Canadian recreational cannabis market. We will achieve this through: Brand Building & Marketing: Implementing strategic marketing campaigns and activations to elevate brand awareness and recognition among Canadian consumers. Product Diversification: Optimizing our product portfolio to cater to diverse and evolving trends and market segments. Distribution Network Optimization: Strengthening our relationships with provincial cannabis boards and key retailers to ensure wider product availability across Canada. 6. Innovation and Consumer Trends: Staying ahead of the curve: Avant Brands will introduce exciting new cultivars, keeping ahead of evolving consumer trends."

07:36 EDT Canopy Growth shareholders approve new class of Exchangeable Shares - Canopy Growth announced the voting results from its special meeting of shareholders held on Friday, April 12. At the meeting, shareholders passed a special resolution authorizing an amendment to the company's articles of incorporation, as amended, in order to, among other things: (i) create and authorize the issuance of an unlimited number of a new class of non-voting and non-participating exchangeable shares in the capital of Canopy Growth. The Exchangeable Shares will not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy Growth but will be convertible into Shares. "With this successful shareholder vote complete, our Canopy USA strategy is advancing and is poised to make Canopy the first and only U.S. listed cannabis company offering shareholders unique exposure to the rapid growth of the U.S. cannabis market," said David Klein, CEO of Canopy Growth. "Canopy USA can now move quickly to acquire its U.S. assets in Wana, Jetty, and Acreage, and we expect Canopy Growth to begin highlighting Canopy USA's financial performance to our shareholders later this year." Added Klein, "Buoyed by recent comments from the President and the Vice-President, Canopy Growth continues to be cautiously optimistic that cannabis will be moved to Schedule III in the near-term. Following this, we expect an immediate enhancement to the cashflow of Wana, Jetty, and Acreage resulting from the removal of the prohibition on business deductions in Section 280 which we expect to help power their growth."

07:35 EDT Nokia, SURF reach 800 Gb/s transmission on existing fiber - Nokia and SURF have successfully reached a single carrier 800Gb/s optical transmission over SURF's existing cross border, multi-vendor research and education network infrastructure. The transmission, based on Nokia's photonic service engine technology, will help accelerate the massive data exchange between the CERN particle accelerator and the NL Tier-1 research IT facilities at SURF and Nikhef, the Dutch National Institute for Subatomic Physics. By reaching 800Gb/s per channel on older fiber varieties, Nokia and SURF prove that existing infrastructure still has tremendous potential, and that legacy optical fibers can be used to meet future capacity demands of the huge data streams generated by international scientific research instruments. The trial was conducted over a 1648 km point-to-point fiber link connecting Amsterdam and Geneva, crossing Belgium and France. The fiber link is part of the SURF-network, which connects national research and education institutes in the Netherlands, such as Nikhef. Additionally, the SURF-network is also well connected to other research networks and experiments worldwide. For this trial, CERN, Nikhef, SURF and the ATLAS LHC experiment have collaborated to include real production workflows that are expected when the High-Luminosity Large Hadron Collider is operational. SURF is preparing its network for CERN's LHC upgrade to the HL-LHC that will become operational in 2029.

07:34 EDT Goldman Sachs reports headcount down 2% in Q1 vs. end of 2023 - Headcount reduction primarily reflects the impact of the sale of GreenSky Holdings, LLC.

07:33 EDT Goldman Sachs reports Q1 FICC revenue $4.32B

07:32 EDT Invivyd receives HCPCS reimbursement codes from CMS covering PEMGARDA - Invivyd announced that the U.S. Centers for Medicare & Medicaid Services, CMS, has granted a Healthcare Common Procedure Coding System, HCPCS, Q code covering product reimbursement for PEMGARDA. In addition, CMS issued a product specific M code covering the administration of PEMGARDA. Both HCPCS codes are effective retroactively to March 22, 2024, the date of emergency use authorization for PEMGARDA. "CMS provides coverage for nearly half of the moderately to severely immunocompromised people at highest risk for severe COVID-19 whom we are targeting, and obtaining a Q code that secures PEMGARDA reimbursement for such a significant population marks another key milestone in our efforts to bring this important molecule to those individuals," said Jeremy Gowler, Interim Chief Executive Officer at Invivyd. "While still in the very early days of the launch, we have already seen exciting initial interest in PEMGARDA from patients and prescribers, sold and shipped product, and engaged in constructive conversations with a range of commercial payors. Momentum is building, and I look forward to providing additional updates on our commercial progress in the months ahead."

07:31 EDT Telos expands enrollment, renewal options by opening new locations - Telos Corporation continues to expand locations to enroll and renew consumers in the TSA PreCheck program by opening two new Florida locations in Wesley Chapel on April 10 and Mount Dora on April 12. Telos now has 28 TSA PreCheck enrollment centers open across the U.S. The launch of enrollment centers in Florida represents the ongoing expansion of Telos' national TSA PreCheck enrollment footprint. "Telos is pleased to open new TSA PreCheck enrollment centers in Florida, bringing the convenience of TSA PreCheck to the backyards of millions of Americans," said John Wood, CEO and chairman, Telos. "Every minute matters during your travel day and TSA PreCheck will help get you to your destination quickly and easily."

07:14 EDT Marinus expects Phase 3 Trust TSC trial of ZTALMY in mid-May 2024 - Marinus expects to complete enrollment in the Phase 3 TrustTSC trial of ZTALMY or ganaxolone, oral suspension CV with approximately 130 patients in mid-May 2024. The Company expects topline results early in the fourth quarter of 2024 and anticipates filing a supplemental New Drug Application to the U.S. Food and Drug Administration in the first half of 2025 with a request for priority review. Marinus also continues to develop a second-generation ganaxolone formulation intended to provide improved pharmacodynamic and pharmacokinetic profiles that could improve safety, efficacy and tolerability and enable less frequent dosing.

07:12 EDT Xtract One says SmartGateway selected by American Bank Center - Xtract One Technologies announced its SmartGateway has been selected to protect all entrances at American Bank Center in Corpus Christi, TX. A multi-purpose indoor arena and convention space designed for concerts, sporting events, professional and amateur rodeos, and other notable events, American Bank Center boasts a 10,000-seat indoor arena and a 138,000-square-foot convention center and is operated by Oak View Group.

07:11 EDT Eagle Pharmaceuticals to present data from Phase III trial of amisulpride - Eagle Pharmaceuticals announced that data from the Company's Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting will be presented at the upcoming American Society of PeriAnesthesia Nurses 2024 National Conference, which is being held April 14-18, 2024, in Orlando, Florida. The data being presented relate to a prespecified pharmacokinetic subset of patients from a Phase III, randomized, multicenter, double-blind, placebo-controlled, parallel-group study in adult surgical patients with moderate to high risk of PONV who failed antiemetic prophylaxis. "The PK data from this subset of patients in this Phase 3 study demonstrate that a single treatment with amisulpride is capable of delivering a sustained response, which we believe is particularly useful in the rescue setting where patients have already failed antiemetic prophylaxis therapy," stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. "Based on what we believe to be encouraging results and corresponding PK data, we expect more healthcare providers to recognize the potential of PONV rescue treatment with amisulpride to enhance confidence in post-surgery and discharge outcomes."

07:09 EDT Marimaca Copper provides update on activities at Marimaca Oxide Deposit - Marimaca Copper provides an update on development activities at the Marimaca Oxide Deposit led by Ausenco Chile, and exploration activities at the Sierra de Medina property block, located ~25km from the MOD. The Company has also commenced exploration trenches and surface sampling activities at the Mercedes satellite target, located approximately 1km north of the MOD. Highlights: Permit engineering, led by Ausenco, informed by final baseline studies and updated project layout progressing to plan; MOD project permitting submission remains on track for early Q3 2024; Project layout is frozen, confirmed by condemnation drilling completed and announced Jan. 16, 2024; The DFS development strategy optimization, led by Ausenco, is near completion; Workstream intended to finalize optimal development strategy for the MOD, focusing on capital intensity and mine planning and targeting a scale-up from the 2020 Preliminary Economic Assessment; DFS remains on track for completion in late Q4 2024. The Company is currently considering strategic options to progress immediately into detailed engineering of the MOD post-DFS in 2025. 2024 work plan remains fully funded. Definitive Feasibility Study geo-metallurgical model in final phases of development with confirmatory metallurgical test-work program. Expands on acid consumption and operability optimizations identified in Geomet 6. To date, four 4m height x 1m diameter column tests each stacked with 1,400 kg of green oxide material completed to generate raffinate for final column test program: Four 4m height columns to finalize optimal crush size for green oxide mineral zones; Four 4m height columns to finalize optimal irrigation rate for green oxide mineral zones; Four 4m height columns confirming optimal parameters set in previous columns for green oxide mineral zones; Fourteen 1m height columns confirming optimal leaching parameters for mixed and enriched mineral zones; In the parallel regional exploration track, geophysics work is underway at the Sierra de Medina property block, located 25km from the MOD; Initial work includes, UAV topography, Resistivity CS-NSAMT and high-resolution mag-drone surveys at key conceptual targets; Geophysics work will be considered and integrated into potential future discovery drilling campaigns. Additionally, initial exploration trenching and surface sampling at the Mercedes East satellite target, located ~1km north of the MOD, has been initiated. Hayden Locke, President and CEO of Marimaca Copper, commented: "The Marimaca Team, in collaboration with Ausenco and Mitsubishi, is moving rapidly toward our 2024 development milestones at the MOD. We continued to progress the MOD toward construction amidst a very constructive macro back-drop for copper. It is an exciting time to be de-risking what is shaping up to be a very high-quality copper development project in the MOD. The Company is currently strategizing to ensure progression of the MOD directly into FEED in 2025, immediately following the completion of the DFS, which would keep us on track for a targeted construction decision in late 2025. On the exploration front, as discussed in our February press release on Sierra de Medina, Sergio Rivera and his team have kicked off initial geophysics to vector on key targets. We are excited about the potential a Sierra de Medina and the implications for Marimaca's exploration pipeline beyond the MOD and it's core satellite targets like Mercedes."

07:08 EDT Ultragenyx announces results from interim Phase 1/2 data of GTX-102 - Ultragenyx Pharmaceutical announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome. Expansion Cohorts at Day 170: Cognition assessed by Bayley-4 showed rapid and clinically significant improvement compared with Natural History data. Day 170 data were consistent with the treatment benefit observed in the Dose-escalation Cohorts at a similar timepoint. Behavior assessed by the Angelman Severity Assessment showed rapid improvement exceeding the treatment benefit observed in the Dose-escalation Cohorts at Day 170. Hyperactivity and noncompliance assessed by the Aberrant Behavior Checklist-Community showed rapid and clinically significant improvement at Day 170 compared with Natural History data, providing further insight into one of the most commonly reported behavioral issues. Sleep assessed by ASA showed rapid and clinically meaningful improvement exceeding treatment benefit observed in the Dose-escalation Cohorts at Day 170. Receptive communication assessed by Bayley-4 showed rapid improvement compared with Natural History data. Day 170 data were consistent with the treatment benefit observed in the Dose-escalation Cohorts at a similar timepoint. Gross Motor function assessed by ASA showed rapid improvement exceeding the treatment benefit observed in the Dose-escalation Cohorts at Day 170. Gross motor assessments as measured by Bayley-4 were not performed at Day 170 in the Expansion Cohorts to reduce patient testing burden and are not included in this analysis at this timepoint. Multi-domain Responder Index analysis across the four domains of Cognition, Receptive Communication, Behavior and Sleep resulted in a total net response of +2.0. The majority of patients had already achieved a total net response of +2 to +4 domains, demonstrating improvement exceeding the minimally important difference threshold in several domains even at this early Day 170 timepoint. Dose-escalation Cohorts up to Day 758: Cognition assessed by Bayley-4 showed continuing long-term improvement compared with Natural History data and exceeded the threshold of clinical significance by many-fold in many patients. Behavior assessed by ASA showed continuing clinically meaningful improvement. Sleep assessed by ASA showed sustained clinically meaningful improvement. Receptive communication measured by Bayley-4 showed sustained and clinically significant improvement compared with Natural History data. Gross motor function assessed by Bayley-4 showed continued and clinically significant improvement compared with previously reported Natural History data. MDRI analysis across the four domains of Cognition, Receptive Communication, Behavior and Sleep resulted in a total net response of +2.0 (p-value = 0.0007) at Day 338. The majority of patients had a total net response of +2 to +4, as well as a 2- to 5-fold improvement over the MID threshold in several domains

07:06 EDT Gritstone publishes interim results from Phase 1/2 study of SLATE - Gritstone bio announced that a paper detailing the development of its "off-the-shelf" neoantigen platform, SLATE, recently published in Nature Medicine. The paper, "A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results," describes a novel immunodominance hierarchy of tumor neoantigens that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS. "The publication of these findings in Nature Medicine highlights the promise of our 'off-the-shelf' or shared neoantigen approach in solid tumors, one of the many elements embedded within our mission to develop the world's most potent vaccines," said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio. "Our team's innovative work to develop, optimize and validate SLATE positions Gritstone with two promising platforms to execute against our neoantigen-directed approach to oncology. It also enabled the pioneering collaboration that we are currently advancing with Dr. Rosenberg of the NCI, a luminary in the field. SLATE is ready for 'plug and play' application across a spectrum of solid tumors and could serve as a great complementary platform to GRANITE, our personalized vaccine program. We continue to have great conviction that both approaches could unlock new levels of immune responses for patients with solid tumors."

07:04 EDT InMode responds to petition to USPTO filed by BTL Industries - InMode responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511. Six months before BTL's petition, InMode sued BTL in the U.S. District Court for the Central District of California alleging that BTL's UltraFemme 360 and EmFemme 360 non-invasive, radio-frequency based feminine rejuvenation products infringe the patent. That litigation is ongoing. InMode's Chief Technology Officer, Dr. Michael Kreindel, commented "The filing of a USPTO petition for Inter Partes review by a defendant accused of patent infringement is commonplace, and something that occurs in most important patent disputes. BTL's petition did not come as a surprise to us, and we look forward to defending the validity of our patent before the USPTO." Kreindel added "We also look forward to continuing our case against BTL in the California district court to protect the valuable technology that our patent covers. We acquired this cutting edge technology from Viveve to complement our own developmental efforts, and when others like BTL use it we take vigorous action."

07:04 EDT Ocular Therapeutix appoints Dugel as President, CEO - Ocular Therapeutix announced that Executive Chairman, Pravin Dugel, MD, is assuming the roles of President and Chief Executive Officer, and that Antony Mattessich is stepping down as President and CEO, effective immediately. In addition to his new responsibilities, Dr. Dugel will continue to serve as a director and as Executive Chairman of Ocular. Pravin U. Dugel, MD has held previous leadership roles including President of IVERIC Bio

07:03 EDT TFF Pharmaceuticals announces data from TFF TAC Phase 2 trial - TFF Pharmaceuticals announced additional data from the ongoing Phase 2 study which is evaluating Tacrolimus Inhalation Powder for the prevention of organ rejection in lung transplant recipients. These new data were presented by Professor Gregory Snell, the lead Principal Investigator of the TFF TAC Phase 2 study, in an oral presentation at the International Society for Heart and Lung Transplantation 44th Annual Meeting at a late breaking clinical science abstract session, on April 13, 2024, in Prague, Czech Republic. TFF TAC - updated Phase 2 data post ISHLT 2024 Meeting: The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity. Part A of the trial is a 12-week treatment period, and Part B is an optional safety extension period. Trial endpoints include safety, tolerability, kidney function, and acute allograft rejection. In March 2024, the Company announced updated data from the first eight patients enrolled in the trial. Today, the Company announced additional data from the trial, including new gene expression data assessing molecular markers of acute rejection, that were presented by Professor Gregory Snell at the ISHLT 2024 Annual Meeting on April 13, 2024. Updated Efficacy: Successful transition of eight of eight patients from oral Tacrolimus to TFF TAC; No evidence of acute rejection: No signs and symptoms suggestive of acute rejection; No use of pulse corticosteroids to treat acute rejection; No deterioration in spirometry suggestive of acute rejection; No chest x-ray findings suggestive of acute rejection; No gene expression evidence of rejection in 4/4 patients with available gene expression data on endobronchial biopsies: Rejection-related genes normalized on TFF TAC in 3/3 patients with abnormal expression of rejection-related genes at baseline while on oral tacrolimus; Rejection-related genes remained normal on TFF TAC in one patient with normal expression of rejection related genes at baseline. 4/4 patients who completed Part A chose to remain on TFF TAC and proceeded to Part B. Updated Safety: No mortality; No TFF TAC discontinuation due to an AE; Majority of TEAEs were Grade 2 or lower in severity; Maintenance of kidney function . Based on these results, TFF Pharmaceuticals plans to open an IND in the US to explore the use of TFF TAC early post-transplant in preparation for a registrational trial.

07:03 EDT Euro Tech Holdings forms BWTS business partnership in Greece - Euro Tech Holdings reported that the company has recently formed a new synergistic "White Label" BWTS business partnership in Greece. The company's majority-owned subsidiary, Yixing PACT Environmental Technology Co., Ltd., has signed an exclusive sales distribution and OEM partnership agreement with ERMA FIRST ESK Engineering Solutions S.A. This partnership has created a synergy effect for both companies as PACT is a UV-based BWTS technology company and complements ERMA FIRST's electrolysis technology. Sales distribution will be focused on 20 countries in Europe, and the company believes this will allow it to achieve quicker penetration in the European market over the coming months.

06:53 EDT Piedmont Lithium receives approvals for proposed Carolina Lithium project - Piedmont Lithium announced that the North Carolina Department of Environmental Quality's, or NCDEQ, Division of Energy, Mineral, and Land Resources, or DEMLR, has issued an approval of our mining permit for the construction, operation, and reclamation of the proposed Carolina Lithium project in Gaston County, North Carolina. DEMLR provided the permit approval following a thorough review of the application submitted by Piedmont on August 30, 2021. The mining permit is subject to conditions both customary and specific to our type of project. "Carolina Lithium is a highly strategic project," said Piedmont Lithium President and CEO Keith Phillips. "Located within both the renowned Carolina Tin-Spodumene Belt and the U.S. Battery Belt, the Project is being designed as a fully integrated mining, spodumene concentrate, and lithium hydroxide manufacturing operation. There are currently no such integrated sites operating anywhere in the world, and the economic and environmental advantages of this strategy are compelling.

06:46 EDT Granite Real Estate Investment and Granite REIT propose internal reorganization - Granite Real Estate Investment Trust and Granite REIT announced that, at the upcoming Joint Annual General and Special Meetings of holders of Granite's stapled units scheduled for June 6, they intend to propose an internal reorganization that would simplify Granite's capital structure by replacing its current Stapled Unit structure with a conventional REIT trust unit structure. The Stapled Unit structure was established in 2013 to accord greater flexibility as to the use for Canadian tax purposes of capital losses. Since this time, a significant portion of those losses have now been utilized. As a result of the Reorganization, Granite REIT expects it will be more comparable to other Canadian real estate investment trusts due to its simplified structure, and that certain investors may therefore be more able or willing to invest in Granite REIT units rather than Stapled Units. Currently, Granite unitholders hold Stapled Units, each of which consists of one Granite REIT unit and one common share of Granite GP. In the Reorganization the two components of each Stapled Unit will be uncoupled, the common shares of Granite GP currently held by Granite unitholders will be automatically exchanged for fractional Granite REIT units and the Granite REIT units will be consolidated back to the number of Stapled Units outstanding before the exchange occurred. Each Granite unitholder will hold a number of Granite REIT units equal to the number of Stapled Units they hold currently, and Granite GP will become a wholly-owned subsidiary of Granite REIT.

06:35 EDT Parsons selected by New Jersey Turnpike Authority to design new Newark bridge - Parsons announced that the New Jersey Turnpike Authority selected the company to serve as final designer for the replacement of the Vincent Robert Casciano Bridge, known as the Newark Bay Bridge. The final design is the first final design contract of the Newark Bay-Hudson County Extension Improvements Program, a critical modernization and safety program that will rebuild the 8.1-mile NJ Turnpike Extension from Interchange 14 in Newark to Jersey Avenue in Jersey City. This replacement is the Turnpike Authority's highest priority, given the condition of the nearly 70-year-old structure, which is at the end of its life. Parsons is leading the design effort from our Newark, NJ office. The replacement of the Newark Bay Bridge represents a significant portion of the Program's first project, which will reconstruct the Extension between Interchange 14 in Newark and Interchange 14A in Bayonne and Jersey City. To mitigate impacts on drivers, the surrounding communities, and the environment, there will be a phased strategy to replace the Newark Bay Bridge that will not increase traffic congestion. A new cable-stayed bridge will be built alongside the existing Newark Bay Bridge, during which time the existing bridge will remain operational. Once the new bridge is completed, the existing bridge will be demolished, and another new cable-stayed bridge will be built in its place.

06:32 EDT Babcock & Wilcox subsidiary awarded $7M contract in Southeast Asia - Babcock & Wilcox announced that its Babcock & Wilcox Renewable Service subsidiary has been awarded a contract valued at more than $7M to upgrade three municipal and commercial waste-fueled boilers and combustion equipment at a waste-to-energy power plant in Southeast Asia. The contract was awarded based on the results of B&W Renewable Service's Front-End Engineering Design, or FEED, study in 2023. B&W Renewable Service will supply new pressure parts, water-cooled wear zones, water soot cleaning equipment, a secondary air system and related equipment to increase the plant's steam production capacity and efficiency, while also reducing emissions. B&W Renewable Service also will advise the customer during the construction and commissioning processes.

06:10 EDT Resideo to acquire Snap One for $10.75 per share - Resideo (REZI) and Snap One (SNPO) announced a definitive agreement pursuant to which Resideo has agreed to acquire Snap One for $10.75 per share in cash, for a transaction value of approximately $1.4B, inclusive of net debt. Upon closing, Snap One will integrate into Resideo's ADI Global Distribution business. The transaction will combine ADI's position in security products distribution and Snap One's complementary capabilities in the smart living market and innovative Control4 technology platforms, which is expected to drive increased value for integrators and financial returns. Together, ADI and Snap One will provide integrators an increased selection of both third-party products and proprietary offerings through an extensive physical branch footprint augmented by industry leading digital capabilities. The transaction is expected to be accretive to Resideo non-GAAP EPS in the first full year of ownership, with revenue growth and margin profile to ADI and Resideo as a whole. Transaction financing has been structured to allow Resideo to preserve financial flexibility for future strategic initiatives. The transaction is valued at approximately $1.4B, including forecasted net debt of Snap One at the closing of approximately $460M. This represents a 7.4x multiple on Snap One's adjusted EBITDA for the twelve months ended December 29, 2023, as further adjusted by including Resideo's projected annual run-rate synergies of $75M. The transaction is expected to be completed in the second half of 2024, and is subject to customary closing conditions, including receipt of applicable antitrust and other regulatory approvals. The transaction has been unanimously approved by the boards of directors of Resideo and Snap One. Private investment funds managed by Hellman & Friedman LLC, holding approximately 72% of the outstanding common shares of Snap One, have executed a written consent to approve the merger, thereby providing the required stockholder approval for the transaction. Resideo intends to use proceeds from committed debt financing, cash on hand, and a $500M perpetual convertible preferred equity investment from Clayton, Dubilier & Rice to fund the transaction. Terms of the CD&R investment include a 7% coupon, payable in cash or payment-in-kind at Resideo's option, and a conversion price of $26.92. Effective upon the closing, CD&R will have the right to designate two members to the Board of Directors of Resideo.

06:06 EDT Shah Capital recommends to appoint two new directors to Novavax board - Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax, has issued an statement saying: "As a long-term strategic investor in Novavax, Shah Capital has been deeply disappointed in its performance and the failure of its leadership to realize shareholder value reflective of Novavax's significant competitive advantages and sizeable market opportunity. Over a period of more than a year, Shah Capital has engaged repeatedly with the board and made several suggestions aimed at addressing self-inflicted problems which have undermined the success and sustainability of the company. However, the board has regrettably been unresponsive. Following this subsequent inaction by Novavax, which is now trading at a near record low and is one of the most shorted stocks on the Nasdaq, Shah Capital has been forced to make public its concerns and call for leadership change. Recognizing this pressing need for Novavax to offer the investment community a more proactive and innovative strategy, Shah Capital is strongly recommending the appointment to the board of two new independent directors: Suresh Katta, founder of Saama and CEO of the company for 25 years, and Venkat Peri, CEO of Quantiva Health a healthcare company that is putting AI and advanced computational sciences at the intersection of medicine, biology, and healthcare economics"

06:05 EDT KBR enters alliance agreement with GeoLith SAS - KBR announced it has signed an alliance agreement with GeoLith SAS to offer its advanced Direct Lithium Extraction, or DLE, technology, Li-Capt. This technology enables zero-emission lithium extraction from untapped sources like geothermal and oil well brines. Under the terms of the agreement, KBR will serve as the exclusive global licensor of GeoLith's Li-Capt technology, which produces pure lithium concentrate and is adaptable to various brine compositions and extraction sources. This technology, in combination with KBR's existing suite of battery material technologies including PureLiSM, a high purity lithium production technology, provides clients with an end-to-end solution to produce battery-grade lithium carbonate or lithium hydroxide monohydrate, essential components for advanced batteries in electric vehicles, from lithium brine feedstock.

06:03 EDT Biden announces preliminary agreement with Samsung to bring semi plants Texas - In a statement from President Joe Biden and the White House, Biden says "I signed the CHIPS and Science Act to restore U.S. leadership in semiconductor manufacturing and ensure America's consumers, businesses, and military maintain access to the chips that underpin our modern technology. But well before the law was passed, I was working to address our supply chain vulnerabilities. This included my trip to the Republic of Korea, where I visited Samsung's Pyeongtaek campus to see one of the largest semiconductor manufacturing facilities in the world. Now, nearly two years later, I'm pleased to announce a preliminary agreement between Samsung and the Department of Commerce to bring Samsung's advanced semiconductor manufacturing and research and development to Texas. This announcement, will unleash over $40B in investment from Samsung, and cement central Texas's role as a state-of-the-art semiconductor ecosystem, creating at least 21,500 jobs and leveraging up to $40M in CHIPS funding to train and develop the local workforce. These facilities will support the production of some of the most powerful chips in the world, which are essential to advanced technologies like artificial intelligence and will bolster U.S. national security. Today's announcement of Samsung's investment in the United States is another example of how my Investing in America agenda and the U.S.-ROK Alliance is creating opportunity in every corner of the country." Reference Link

05:23 EDT Encore Wire to be acquired by Prysmian for $290.00 per share in cash - Encore Wire announced that it has entered into a definitive merger agreement under which Prysmian will acquire Encore Wire for $290.00 per share in cash. The transaction represents a premium of approximately 20% to the 30-day volume weighted average share price, or VWAP, as of Friday, April 12 and approximately 29% to the 90-day VWAP as of the same date. At the terms of the transaction, Encore Wire's implied enterprise value is approximately EUR 3.9B representing a multiple of 8.2x EV/2023A EBITDA and 6.3x EV/2023A EBITDA including run rate synergies. Following closing of the transaction, Prysmian expects to maintain a significant presence at Encore Wire's vertically-integrated, single-site, McKinney, Texas campus. Based on pro forma aggregated results for the twelve months ended December, 2023, the combined group would have posted net sales of over EUR 17.7B and adjusted EBITDA of approximately EUR 2.1B. The transaction will be financed through a mix of cash on Prysmian's balance sheet and newly committed debt facilities. The transaction, which has been unanimously approved by each company's board of directors and recommended to its shareholders by Encore Wire's board of directors, is expected to close in the second half of 2024, subject to approval of Encore Wire's shareholders representing at least a majority of the outstanding shares, regulatory approvals, and other customary closing conditions. Under the terms of the agreement, Encore Wire may solicit alternative acquisition proposals from third parties during a 35-day "go-shop" period following the date of execution of the merger agreement. There can be no assurances that the "go-shop" will result in a superior proposal. Encore Wire does not intend to disclose developments related to the solicitation process until it determines whether such disclosure is appropriate or is otherwise required.

05:15 EDT Genentech announces STARGLO study meets primary endpoint - Genentech, a member of Roche, announced the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory, or R/R, diffuse large B-cell lymphoma, or DLBCL, who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, lived longer when treated with Columvi in combination with gemcitabine and oxaliplatin versus Rituxan in combination with GemOx. Safety of the combination appeared consistent with the known safety profiles of the individual medicines. The data will be submitted to health authorities and shared at an upcoming medical meeting. Columvi was the first fixed-duration bispecific antibody to receive accelerated approval by the FDA and conditional marketing authorization from the European Commission to treat people with R/R DLBCL after two or more lines of systemic therapy. These approvals were based on positive results of Columvi as a monotherapy from the pivotal Phase I/II NP30179 study in patients with R/R DLBCL who had previously received two or more prior treatments. Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to be off-the-shelf and ready for infusion, so patients can start treatment soon after diagnosis. This is particularly important for patients with highly aggressive disease who are at risk of rapid disease progression. Columvi is given as a fixed-duration treatment, offering people with R/R DLBCL who have failed two or more lines of therapy a treatment end date and the possibility of a treatment-free period, unlike continuous treatments.

05:10 EDT CME Group reports Q1 international ADV 7.4M contracts - CME Group announced that its quarterly international average daily volume, or ADV, reached a record 7.4M contracts in Q1, up 2% year on year. Reflecting all trading reported from outside the United States, volume was driven largely by 38% growth in energy products, a 29% increase in agricultural products, and 7% growth in metals.